Fiera Capital Corp Has $85.84 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Fiera Capital Corp trimmed its stake in shares of argenx SE (NASDAQ:ARGX) by 4.4% during the third quarter, Holdings Channel reports. The firm owned 158,353 shares of the company’s stock after selling 7,242 shares during the period. Fiera Capital Corp’s holdings in argenx were worth $85,840,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ARGX. Envestnet Portfolio Solutions Inc. grew its position in argenx by 21.5% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 1,300 shares of the company’s stock valued at $512,000 after acquiring an additional 230 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in argenx by 5.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 2,916 shares of the company’s stock valued at $1,148,000 after purchasing an additional 152 shares during the last quarter. Headlands Technologies LLC acquired a new position in argenx in the first quarter valued at about $397,000. US Bancorp DE grew its stake in argenx by 15.6% during the first quarter. US Bancorp DE now owns 3,782 shares of the company’s stock worth $1,489,000 after buying an additional 511 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of argenx by 6.3% during the first quarter. ProShare Advisors LLC now owns 2,181 shares of the company’s stock worth $859,000 after buying an additional 129 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Up 0.5 %

NASDAQ ARGX traded up $3.20 during trading on Friday, reaching $594.64. 83,429 shares of the stock traded hands, compared to its average volume of 307,393. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $611.22. The firm has a market cap of $35.56 billion, a price-to-earnings ratio of -672.09 and a beta of 0.61. The stock’s 50-day moving average price is $545.48 and its 200 day moving average price is $472.18.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the prior year, the company earned ($1.25) EPS. Analysts anticipate that argenx SE will post 2.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of research analyst reports. Baird R W lowered argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Oppenheimer increased their target price on argenx from $560.00 to $646.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a report on Monday. Raymond James reiterated a “strong-buy” rating and set a $605.00 price target on shares of argenx in a research report on Thursday, October 10th. Finally, Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and raised their price objective for the company from $439.00 to $715.00 in a research report on Tuesday. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $615.50.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.